Launched in 2025, the program operates through a network of 15 clinics across the United States. It functions under the ACT for ALS initiative, with backing from the National Institute of Neurological Disorders and Stroke. By prioritizing patients who lack other disease-modifying treatment options, the program aims to bridge the gap between experimental research and clinical reality.
In section Releases
WideTrial Closes Enrollment for ALS Expanded Access Program
Two hundred patients across 27 states have joined the SEANOBI-ALS program, reaching the study's enrollment capacity in under 13 months. The initiative provides the investigational drug MN-166, also known as ibudilast, to individuals who remain ineligible for traditional clinical trials due to strict entry criteria or geographic barriers.
Participants currently enrolled will maintain their treatment protocols through early 2027. Following the final follow-up, WideTrial plans to analyze the collected data to inform future scientific publications. Given the rapid uptake of this cohort, the company is already evaluating new expansion opportunities and expects to launch at least one additional large-scale program in 2027.
Comments (0)
No comments yet. Be the first!